Location of Repository

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review

By Gregory E Peterson

Abstract

Gregory E PetersonDepartment of Internal Medicine, Des Moines University, USAObjective: To review insulin detemir for clinical use to better manage patients with type 1 and type 2 diabetes.Methods: A MEDLINE search, in English, from June 30, 2006 to December 1, 2008, using the terms “insulin analogs,” “insulin detemir” and “long-acting insulin analog.”Results: Insulin detemir improves glycemic control, based on HbA1C reduction and fasting glucose levels, without increasing the risk of hypoglycemia and weight gain. Insulin detemir has lower glycemic variability, with less intra-subject variability in blood glucose levels in patients with type 1 and type 2 diabetes, without increasing the risk of hypoglycemia. When added to oral anti-diabetes agents (OADs) in type 2 diabetes, insulin detemir demonstrates superiority to other basal insulin options.Conclusion: Insulin detemir appears to provide better glycemic control with a lower risk of hypoglycemia and less weight gain in the treatment of patients with type 1 and type 2 diabetes.Keywords: type 1 diabetes, type 2 diabetes, insulin analogs, insulin detemi

Topics: Medicine (General), R5-920, Medicine, R, DOAJ:Medicine (General), DOAJ:Health Sciences, Specialties of internal medicine, RC581-951
Publisher: Dove Medical Press
Year: 2009
OAI identifier: oai:doaj.org/article:0ed4823db64e443997f6940b7a08960c
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1178-7007 (external link)
  • http://www.dovepress.com/analo... (external link)
  • https://doaj.org/article/0ed48... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.